Literature DB >> 11470162

The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron.

H K Lum1, K L Lee.   

Abstract

The highly conserved, ubiquitous high mobility group protein HMGB1 (formerly named as HMG1) is an architectural transcription factor encoded by a single functional gene in human. HMGB1 is expressed in almost all cell or tissue types studied. In general, it is expressed at a basal level in most cells but at a slightly elevated level of 2--3-fold in actively proliferating tissues or estrogen stimulated breast cancer cells. To understand the regulatory mechanism controlling expression of the human HMGB1 gene, we cloned and analyzed the upstream region as well as the first intron of this gene. We found that transcription of the human HMGB1 gene in the breast cancer MCF-7 cells starts at one major site 57 nucleotides upstream from the first exon-intron boundary. Expression of the human HMGB1 gene is under the control of a very strong TATA-less promoter, which has an activity more than 18-fold that of the SV40 promoter. Immediately upstream, a silencer element is present. This silencer can repress the activity of the HMGB1 promoter down to just one-sixth. The first intron of the human HMGB1 gene contains enhancer elements, which can increase the human HMGB1 promoter activity by 2--3-fold. We postulate that the human HMGB1 gene is capable of being expressed at a very high level. The basal level of expression observed in most cells is probably a result of the strong promoter being held in check by the silencer. The 2--3-fold increase in HMGB1 expression observed in proliferating cells or breast cancer cells stimulated by estrogen may probably result from the action of the enhancer elements in intron 1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470162     DOI: 10.1016/s0167-4781(01)00243-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  HMGB1 in hormone-related cancer: a potential therapeutic target.

Authors:  Madhuwanti Srinivasan; Souresh Banerjee; Allison Palmer; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam
Journal:  Horm Cancer       Date:  2014-04-10       Impact factor: 3.869

2.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 3.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 4.  The implication and potential applications of high-mobility group box 1 protein in breast cancer.

Authors:  Moonindranath Sohun; Huiling Shen
Journal:  Ann Transl Med       Date:  2016-06

5.  Excessive mechanical stress increases HMGB1 expression in human lung microvascular endothelial cells via STAT3.

Authors:  Rachel K Wolfson; Brandon Mapes; Joe G N Garcia
Journal:  Microvasc Res       Date:  2013-12-24       Impact factor: 3.514

6.  Secreted HMGB1 from Wnt activated intestinal cells is required to maintain a crypt progenitor phenotype.

Authors:  Karen R Reed; Fei Song; Maddy A Young; Nurudeen Hassan; Daniel J Antoine; Nesibe-Princess B Gemici; Alan R Clarke; John R Jenkins
Journal:  Oncotarget       Date:  2016-08-09

7.  Effects of HMGB-1 overexpression on cell-cycle progression in MCF-7 cells.

Authors:  Sarah Yoon; Jin Young Lee; Byung-Koo Yoon; Duk Soo Bae; Doo Seok Choi
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

8.  Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines.

Authors:  Al-Madhagi Radia; Al-Madhagi Yaser; Xiaoqian Ma; Juan Zhang; Cejun Yang; Qiong Dong; Pengfei Rong; Bin Ye; Sheng Liu; Wei Wang
Journal:  Int J Mol Sci       Date:  2013-04-11       Impact factor: 5.923

9.  Bench-to-bedside review: High-mobility group box 1 and critical illness.

Authors:  Mitchell P Fink
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 10.  PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1.

Authors:  Shibo Ying; Xiang Xiao; Tianhui Chen; Jianlin Lou
Journal:  PPAR Res       Date:  2016-08-02       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.